Cytek Biosciences (CTKB) Liabilities and Shareholders Equity (2020 - 2026)

Cytek Biosciences (CTKB) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $449.1 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 6.94% year-over-year to $449.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.9 billion (down 2.97% YoY) and the FY2025 annual result came in at $461.5 million, down 7.6% from the prior year.
• Liabilities and Shareholders Equity declined to $449.1 million in Q1 2026, from $461.5 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $525.1 million in Q2 2023 to a low of $449.1 million in Q1 2026.
• A 5-year average of $494.6 million and a median of $493.3 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity jumped 114.01% — and 2024, when it decreased 7.87%.
• Tracing CTKB's Liabilities and Shareholders Equity over 5 years: stood at $519.5 million in 2022, then retreated by 4.82% to $494.5 million in 2023, then rose by 1.02% to $499.5 million in 2024, then declined by 7.6% to $461.5 million in 2025, then decreased by 2.69% to $449.1 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $449.1 million (Q1 2026), $461.5 million (Q4 2025), and $494.9 million (Q3 2025), per Business Quant data.